Elanco Animal Health Incorporat
ELAN
Positions held
Your positionsELAN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Elanco's focus on the animal health sector positions it well within a growing industry that is increasingly recognized for its importance in food safety and animal welfare.
- Elanco's revenue for Q2 2026 was $1.368 billion, consistent with the previous quarter, indicating stability in sales.
- The gross margin improved to 58.3% in Q2 2026, up from 57.3% in Q1 2026, reflecting better cost management.
- Elanco faces significant competition in the animal health market, which could pressure margins and market share.
- The company reported a net income loss of $276 million for Q4 2025, highlighting ongoing profitability challenges.
- Elanco's operating margin decreased to 8.6% in Q2 2026, down from 12.3% in Q1 2026, indicating potential operational inefficiencies.
Fundamentals
| Market cap | $11.26B | Enterprise value | $14.96B | Trailing P/E | — | Forward P/E | 17.54 |
| PEG | 4.04 | Price / book | 1.71 | Beta | 1.71 | Dividend yield | 0.00% |
| Revenue growth | 10.2% | Earnings growth | 440.5% | Gross margin | 55.4% | Operating margin | 8.6% |
| Profit margin | -4.0% | ROE | -3.0% | ROA | 1.6% | Debt / equity | 0.64 |
| Current ratio | 2.05 | Free cash flow | $826.88M | Analyst recommendation | strong_buy | Mean target | $31.00 |
| 52w high | $27.98 | 52w low | $19.40 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.4B | $1.1B | $1.1B | $1.2B | — |
| Op margin | 8.6% | 12.3% | 1.7% | 2.4% | 6.8% | — |
| Net income | $54.0M | $57.0M | -$276M | -$34.0M | $11.0M | — |
| Gross margin | 58.3% | 57.3% | 51.5% | 53.4% | 57.5% | — |
| Gross profit | $798M | $785M | $589M | $607M | $713M | — |
| Operating income | $118M | $169M | $19.0M | $27.0M | $85.0M | — |
- Revenue -0% vs prior quarter ($1.4B vs $1.4B).
- Gross margin 58.3% (was 57.3% prior quarter).
- Operating margin compressed to 8.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.7B | $4.4B | $4.4B | $4.4B | — |
| Op margin | 5.3% | 5.7% | 7.4% | 8.7% | — |
| Net income | -$232M | $338M | -$1.2B | -$78.0M | — |
| Gross margin | 55.0% | 54.9% | 56.3% | 56.6% | — |
| Gross profit | $2.6B | $2.4B | $2.5B | $2.5B | — |
| Operating income | $252M | $251M | $326M | $384M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · What Growing Up on a Farm Taught Elanco’s CEO
2026-10-06 · 2 Cash-Producing Stocks for Long-Term Investors and 1 Facing Headwinds
2026-10-05 · 1 Mid-Cap Stock to Keep an Eye On and 2 We Ignore
2026-09-26 · Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground
2026-09-17 · Elanco to Participate in BofA Securities Global Healthcare Conference 2026
2026-09-15 · 3 Reasons to Sell ELAN and 1 Stock to Buy Instead
2026-09-14 · Is Elanco Animal Health (ELAN) Undervalued As Growth Expectations Meet A Recent Pullback?
2026-09-11 · Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement
2026-09-10 · Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
Price (daily)
Full chart · RSI · MACD · patterns